[The use of immune checkpoint inhibitors in routine oncology].

CONCLUSION: Clinical benefits for only a part of patients treated with immune checkpoint inhibitors. The understanding of primary and secondary mechanisms of resistance to immune checkpoint inhibitors has just begun to evolve. Combination strategies of immune checkpoint inhibitors with e.g. chemotherapy, new immune checkpoint inhibitors (e.g. anti-LAG3 antibody) or targeted therapies (e.g. CDK4/6, PARP inhibitors) to improve efficacy are under clinical investigation. Reliable and predictive biomarkers are urgently needed. PMID: 32936368 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Tags: Z Rheumatol Source Type: research